Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction
Atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) frequently coexist, creating a cycle of electrical and mechanical deterioration. AF can reduce ventricular filling, eliminate atrial contraction, increase heart rate, and promote irregular ventricular activation. In turn, elevated filling pressures, atrial enlargement, fibrosis, and neurohormonal activation make AF more persistent and difficult to control.
For selected patients, catheter ablation has become an important rhythm-control strategy rather than a treatment reserved only for drug-refractory symptoms. Pulmonary vein isolation (PVI) remains the procedural foundation, but the decision to intervene should account for ventricular function, AF duration, atrial substrate, comorbidities, procedural risk, and the likelihood of maintaining sinus rhythm.
The strongest clinical rationale is often improvement in functional status and prevention of tachycardia-mediated or AF-mediated cardiomyopathy. However, ablation does not remove the need for guideline-directed heart failure therapy or stroke prevention. Its benefits depend on careful patient selection, contemporary procedural practice, and structured follow-up.
Why AF has greater consequences in HFrEF
Loss of atrial systole is particularly important when ventricular filling is already impaired. A rapid or irregular ventricular response can shorten diastolic filling time, increase mitral regurgitation, and worsen pulmonary congestion. Persistent AF may also produce ventricular dysfunction through tachycardia-induced cardiomyopathy, even when the initial ejection fraction reduction was caused by another process.
The relationship is bidirectional. HFrEF increases left atrial pressure and promotes atrial stretch, inflammation, fibrosis, and electrical remodeling. These changes support sustained AF and reduce the probability that antiarrhythmic medication alone will restore durable sinus rhythm. AF-related remodeling can continue even when symptoms are modest, making objective assessment important.
A rhythm-control strategy may be especially relevant when the decline in left ventricular function appears disproportionate to coronary disease or valvular pathology, when rapid ventricular rates have been difficult to control, or when symptoms and exercise limitation persist despite appropriate medical treatment. The possibility of reversible AF-mediated cardiomyopathy should influence the timing of referral.
Evidence supporting an ablation-first discussion
Randomized and prospective studies have generally shown that AF ablation can improve outcomes in carefully selected patients with HFrEF. In CASTLE-AF, patients with symptomatic AF, reduced ejection fraction, and implanted defibrillator or resynchronization-device monitoring experienced fewer deaths or heart-failure hospitalizations after ablation than with medical therapy. The trial also reported improvements in left ventricular function and maintenance of sinus rhythm.
Other studies, including AATAC and analyses of the CABANA heart-failure population, support improvements in rhythm control, symptoms, quality of life, and ventricular performance. RAFT-AF produced a more neutral result for its composite clinical endpoint, illustrating that outcomes vary according to patient characteristics, ablation strategy, rhythm-monitoring intensity, and the medical therapy used in the comparison group.
These findings do not mean that every patient with HFrEF should undergo an invasive procedure. The contemporary evidence supports an individualized discussion, particularly for symptomatic paroxysmal or persistent AF, suspected AF-mediated cardiomyopathy, repeated heart-failure admissions, or intolerance and inefficacy of antiarrhythmic drugs. Clinicians can review evolving trials and focused reviews through the journal’s arrhythmia research collection.
Selecting patients and preparing for ablation
Before ablation, the clinical team should establish whether AF is a major contributor to ventricular dysfunction. This requires review of prior ejection-fraction measurements, ventricular rate trends, ischemic evaluation when indicated, valvular disease, alcohol exposure, sleep apnea, thyroid function, hypertension, diabetes, obesity, and cardiotoxic medications. Cardiac magnetic resonance imaging may help identify scar or infiltrative disease, although its availability and clinical role vary.
The AF pattern matters. Patients with shorter AF duration, smaller left atrial volume, limited fibrosis, and fewer comorbidities generally have a greater probability of maintaining sinus rhythm. Persistent and long-standing persistent AF can still be treated successfully, but they often require more extensive substrate management and have higher recurrence rates. Severe right-sided disease, advanced pulmonary hypertension, substantial ventricular scar, or terminal noncardiac illness may shift priorities toward symptom control and heart-failure care.
Heart-failure therapy should be optimized before and after the procedure. This may include an angiotensin receptor-neprilysin inhibitor or another renin-angiotensin system treatment, evidence-based beta blockade, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter 2 inhibitor when appropriate. Device therapy should be assessed independently. A patient who may benefit from cardiac resynchronization should not have that decision delayed while awaiting an ablation outcome.
Procedural strategy and pulmonary vein isolation
PVI aims to electrically disconnect the pulmonary veins from the left atrium, preventing or isolating common AF triggers. Radiofrequency point-by-point ablation and cryoballoon ablation are established approaches, while newer pulsed-field techniques are increasingly used in some centers. The choice depends on operator experience, anatomy, equipment, patient factors, and local safety data.
In HFrEF, efficient procedures and avoidance of collateral injury are important. Operators must consider esophageal protection, phrenic nerve injury, vascular complications, tamponade, stroke, and fluid balance. General anesthesia or deep sedation may improve procedural stability, but perioperative management should account for congestion, renal function, pulmonary disease, and hemodynamic reserve.
PVI alone is often appropriate for paroxysmal AF and remains the core treatment for persistent AF. Additional lesion sets, posterior-wall isolation, linear ablation, or ablation of complex electrograms may be considered in selected cases, but broader ablation does not consistently improve outcomes for every patient and can increase procedure time and risk. Durable lesion formation and careful confirmation of pulmonary vein entrance and exit block are more important than simply increasing lesion quantity.
Trigger evaluation can become particularly relevant when AF recurs after apparently successful PVI. A useful overview of non-pulmonary triggers discusses how superior vena cava, left atrial appendage, coronary sinus, ligament of Marshall, and other sites may contribute in selected patients. These targets require a clear electrophysiologic rationale rather than routine empiric treatment.
| Clinical consideration | Why it matters in HFrEF | Practical implication |
|---|---|---|
| Ejection fraction and trajectory | A rapid decline may indicate reversible AF-mediated cardiomyopathy | Compare serial imaging and rate history |
| AF pattern and duration | Persistent AF is associated with greater atrial remodeling | Set realistic expectations about repeat procedures |
| Left atrial size and fibrosis | Greater substrate burden predicts recurrence | Use imaging and rhythm history for risk discussion |
| Heart-failure treatment | Medical therapy reduces congestion and adverse remodeling | Optimize therapy before and after ablation |
| Device status | ICD or CRT devices can support monitoring and ventricular management | Coordinate electrophysiology and device planning |
| Anticoagulation | Stroke risk persists even when sinus rhythm is restored | Base treatment on thromboembolic risk, not apparent rhythm alone |
Managing anticoagulation and the early recurrence period
Periprocedural anticoagulation is central to safe AF ablation. Patients are usually maintained on uninterrupted or minimally interrupted direct oral anticoagulant therapy, or carefully managed warfarin when appropriate. Intraprocedural unfractionated heparin is used to achieve adequate activated clotting times during left atrial work. The exact protocol should follow current guidance and local expertise.
Anticoagulation is generally continued for at least the early healing period after ablation. Longer-term therapy should be determined by thromboembolic risk, including heart failure, hypertension, age, diabetes, prior stroke, vascular disease, and sex-related risk considerations. Restoration of sinus rhythm or absence of symptoms does not by itself justify stopping anticoagulation.
Early atrial tachyarrhythmias are common during the first weeks after ablation and do not always represent definitive treatment failure. Antiarrhythmic drugs may be continued temporarily, and cardioversion can be appropriate for sustained symptomatic recurrence. Severe dyspnea, syncope, hypotension, neurologic symptoms, chest pain, or signs of worsening congestion require urgent assessment rather than routine observation.
Measuring recovery after rhythm control
Ablation success should be assessed with more than a single electrocardiogram. Symptoms, exercise capacity, heart-failure admissions, natriuretic peptide levels, ambulatory monitoring, device data, and serial echocardiography can provide complementary information. Left ventricular recovery may take several months, particularly when remodeling has been longstanding.
A meaningful response may include fewer hospitalizations, improved functional class, lower resting or exertional heart rate, better quality of life, and increased ejection fraction. In patients with an ICD or CRT device, interrogation can reveal AF burden and support decisions about rhythm management. Consumer wearables may identify episodes, but their readings should be interpreted alongside clinically validated monitoring.
Recurrence does not automatically mean that treatment has failed. Repeat ablation may be considered when recurrent AF remains symptomatic, promotes ventricular dysfunction, or limits heart-failure management. The decision should account for the mechanism of recurrence, pulmonary vein reconnection, non-pulmonary triggers, atrial substrate, procedural risk, and the patient’s goals.
Integrating ablation into multidisciplinary care
The best results come from coordinated care involving electrophysiologists, heart-failure specialists, imaging experts, anesthesiologists, device teams, nurses, and primary clinicians. Shared decisions should explain expected benefits, recurrence risk, procedural complications, alternatives, and the possibility of a second procedure. The clinical environment and educational mission of the Journal of Arrhythmia reflect this need for collaboration across arrhythmia practice and cardiovascular medicine.
Risk-factor treatment is part of rhythm control, not an optional adjunct. Weight reduction when appropriate, treatment of obstructive sleep apnea, blood-pressure control, diabetes management, alcohol reduction, smoking cessation, and regular physical activity can improve atrial remodeling and reduce recurrence. These interventions also support heart-failure prognosis independently of AF status.
A practical care pathway should include:
- Confirm the AF burden, mechanism, and contribution to reduced ventricular function.
- Optimize guideline-directed HFrEF treatment and evaluate indications for ICD or CRT.
- Discuss PVI and alternative rhythm-control strategies using individualized recurrence and risk estimates.
- Maintain appropriate anticoagulation and monitor rhythm, ventricular function, symptoms, and congestion after ablation.
Catheter ablation offers a clinically meaningful opportunity for selected people with HFrEF and AF, particularly when AF is symptomatic, persistent, difficult to rate-control, or suspected to be driving ventricular decline. Its value is greatest when integrated with comprehensive heart-failure treatment, stroke prevention, risk-factor modification, and objective long-term monitoring. Clinicians and trainees can use current peer-reviewed evidence and procedural guidance to refine patient selection and build safer, more effective rhythm-control pathways.